Abstract | OBJECTIVE: AIM: METHODS: RESULTS: A total of 106 patients were enrolled and 101 (59 male, 42 female, mean age=40 +/- 11 years) completed the study. Endoscopic findings and demographic data were comparable in both groups. Intention-to-treat eradication rates were 75% and 55% (P=0.03) and per protocol eradication rates were 82 and 56% (P=0. 006) in the RABF and RABM groups, respectively. Side-effects were reported by 13 patients (27%) in the RABF group (one stopped treatment) compared to five patients (10%) in the RABM group (P=0. 04). CONCLUSION:
|
Authors | R Malekzadeh, R Ansari, H Vahedi, F Siavoshi, B Z Alizadeh, M R Eshraghian, A Vakili, M Saghari, S Massarrat |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 14
Issue 3
Pg. 299-303
(Mar 2000)
ISSN: 0269-2813 [Print] England |
PMID | 10735922
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Drug Combinations
- Metronidazole
- Furazolidone
- Urease
|
Topics |
- Adult
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Drug Combinations
- Duodenal Ulcer
(drug therapy, microbiology)
- Female
- Furazolidone
(adverse effects, therapeutic use)
- Helicobacter Infections
(drug therapy, microbiology)
- Helicobacter pylori
- Humans
- Male
- Metronidazole
(adverse effects, therapeutic use)
- Prospective Studies
- Urease
(analysis)
|